

December 15, 2017

## Announcements

### Happy Holidays!

I want to take the time to wish you all a very happy holiday season. It was wonderful to be able to celebrate with so many of you earlier this week at our annual holiday party at the Peabody Museum. We had over 620 people join us at the celebration! A special thanks to Anna Raso and Amanda Schwartz for their planning of the evening at the Peabody.

Thank you all for everything you do to support the research, education, and patient care mission of Yale Cancer Center and Smilow Cancer Hospital each day. Enjoy the holiday season with your loved ones and families and I look forward to an exciting 2018 with all of you.

### New Staging Guidelines

The American Joint Committee on Cancer (AJCC) has issued new staging guidelines, which will be implemented in the new year. Beginning January 1, all eligible, newly diagnosed cases will be staged using the AJCC 8th Edition Cancer Staging System. A summary of the new system is located at the beginning of each disease-focused chapter of the Staging Manual. It is important that all physicians review these guidelines and are familiar with the changes before the implementation takes place. Terri Vega, Manager of our Tumor Registry, provided an introductory overview of the changes during a recent Grand Rounds, which is available online. I encourage you to watch her presentation and to reach out to her with questions. Additional discussions will be ongoing during individual tumor boards in the coming weeks.

*from the desk of*  
**Charles S. Fuchs, MD, MPH**  
Director, Yale Cancer Center  
and Physician-in-Chief  
Smilow Cancer Hospital

Yale  
NewHaven  
Health  
Smilow Cancer  
Hospital

Yale **CANCER**  
**CENTER**  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

### Recent News

[News Center >>](#)

### LATEST ARTICLES:

[Grand Rounds Presentation >>](#)

In addition, the link below is for the physician section of the AJCC website. The website includes free articles and webinars that may be of interest to you.

[AJCC content >>](#)

### **Class of '61 Cancer Research Award**

Valentina Greco, PhD, Associate Professor of Genetics, Dermatology, and Cell Biology and a member of Yale Cancer Center's Signal

Transduction Research Program, has been selected to receive the 2017 Class of '61 Cancer Research Award. This annual award

recognizes significant accomplishments in cancer research at Yale University by a young member of the faculty, coupled with the expectation for future outstanding contributions to our understanding of the causes and cures for cancer. Valentina is internationally recognized for her invention of a new technique to study cell growth, migration, and death in living animals, and for her application of these methods to examine the fundamental processes that control the formation and resolution of tumors in skin.



### **Pancreatic Cancer CME Symposium**

Please reserve Friday, February 2 for a CME Symposium on the Multidisciplinary Management of Pancreatic Cancer at Yale's West Campus. Online registration information will be available shortly, to register early, please contact [Eliza Folsom](#).

[Symposium Agenda >>](#)

## **Notables**



**Pediatric cancer providers give medical marijuana a cautious thumbs-up**

[Read More >>](#)



**Stahl honored at 59th American Society of Hematology Annual Meeting**

[Read More >>](#)



**Yale doctor creates new weapons to kill cancer**

[Read More >>](#)

**Xavier Llor, MD**, Associate Professor of Internal Medicine (Gastroenterology) and Co-Director of the Cancer Genetics and Prevention Program, has been elected for a two-year term to the Steering Committee of the National Colorectal Cancer Roundtable (NCCRT). The NCCRT was established by the American Cancer Society and the Centers for Disease Control and Prevention and is a national coalition of over 200 organizations dedicated to reducing the incidence of and mortality from colorectal cancer in the U.S. The Steering Committee provides strategic guidance to the NCCRT.

## Employee Profile: Krista Bello

Krista Bello, RN, OCN, has served as a nurse at the Smilow Cancer Hospital Care Center at Shoreline Medical Center in Guilford for the last six years, and she has enjoyed many of the benefits that come with working in a smaller care center.



The Guilford Care Center is busy and fast-paced. Every day from 8:30 a.m. to 5:00 p.m., Krista handles 8-12 ambulatory patients for their routine treatments, which range from blood work, assessments, and port flushes, to getting patients set up for chemotherapy. While it is a very small, yet snug care center, construction recently began that will renovate the existing center and expand the square footage, allowing this site to become a 19-chair facility - a very exciting development, says Krista.

Krista first started with Yale New Haven Hospital in 2009 as a clinical nurse on 9 West, and when Smilow opened, she relocated to NP 12. On the 12th floor, she worked



**Yale Cancer Center research highlighted at 2017 SABCS**


[Read More >>](#)



**Be a Health Angel • Give Back Today**

**Be a Health Angel and Give Back**


[Read More >>](#)



**Combining machine and nanoparticles for better transplant outcomes**

[Read More >>](#)

**Join Yale Cancer Center on Facebook**





with a patient population who was very ill with solid tumors (lung, colon, breast, brain) and was receiving end-of-life care. Due to the acute nature of this floor, work was very intense and Krista became accustomed to blocking out all emotion. After three and a half years, Krista received the opportunity to work closer to her home on the shoreline, and she transferred to the Smilow Care Center in Guilford.

Working at the care center, Krista feels she can make a difference in the lives of her patients. "I am helping them on their journey," she says. "I can make a scary and confusing time become a clearer process for the patient, which helps them persevere. Sitting with them and holding their hand and helping them feel normal, it's a wonderful feeling to know that I can make a difference and it gives me gratification that I can help."

Unfortunately, Krista herself would soon become someone in need of support. She and her husband experienced a tragic loss when their son, Bryce, who was just 45 days old, passed away due to a genetic disorder. Work became her saving grace and support system. From the doctors and staff, to even her patients, everyone rallied around her and gave her space to grieve and love when she needed it most.

"This is a special place. Going through this experience has made me a more compassionate nurse. It has given me empathy and the understanding that caring for patients is a rare experience."

## #OOTBTHANKS

### LATEST POSTS:

The Survivorship Clinic at Smilow Cancer Hospital is the only resource of its kind for adult cancer survivors in Connecticut. Our specialists are trained to address the unique concerns of cancer survivors, and we would love to meet you whether you have just completed treatment, received your diagnosis decades ago, or are living with cancer as a chronic condition.

### Did you know...?



The Smilow Survivorship Clinic is the only dedicated, multidisciplinary resource for adult cancer survivors in the state of Connecticut

[Read More >>](#)

Watch Yale Cancer Center and SCH doctor Amer Zeidan on CBS Atlanta (cbs46.com) talking about the latest in blood cancer research



[Read More >>](#)

Tune in to Yale Cancer Answers this week for a special on "Myths in Research and Media," with Dr. Francis Wilson!



### #OOTB: Annette Komlo

YCC #OUTOFTHEBLUETHANKS recently recognized Annette Komlo, CCRP, a Clinical Research Assistant in the Clinical Trials Office. Annette recently received glowing praise from a current research partner and Yale sponsor highlighting her excellent data quality and query management, something that is considered invaluable in ongoing studies. Thank you, Annette!

*Yale Cancer Center's #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. All nominations should be submitted to the Director's Office c/o [Anna Raso](#).*

## Funding Opportunities

### Analyzing and Interpreting Clinician and Patient Adverse

#### Event Data to Better Understand Tolerability (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative

that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Accelerate research that can

## Yale Cancer Answers

"Myths in Research and Media"

[Read More >>](#)

Take your health into your own hands and join Stand Up To Cancer and Smilow Cancer Hospital in celebrating

#CancerScreenWeek! Talk to your doctor, visit our website, or call us today to learn more about what screenings you can do today to protect your health in the future.



DECEMBER 4-8, 2017



## Join Smilow Cancer Hospital for Cancer Screen Week

Call us for more information: (203) 200-3030

[Read More >>](#)

As the temperature continues to cool off, check out our recipes for stews and soups to keep you warm! Side effects from cancer and treatment can affect how you eat, and the Smilow Cancer Hospital Nutrition Cookbook offers healthy and delicious meal ideas to help you feel your

identify approaches to monitor and manage patient-reported symptoms.

**Letter of Intent and Application Deadlines:**

December 17, 2017; January 17, 2018

[Learn More >>](#)

**Coordinating Center for Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (U24)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory.

**Letter of Intent and Application Deadlines:**

December 17, 2017; January 17, 2018

[Learn More >>](#)

**Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory.

**Letter of Intent and Application Deadlines:**

December 17, 2017; January 17, 2018

[Read More >>](#)

**Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS): Coordinating Center (U24)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and


strongest.



[Read More >>](#)

Bill Reese has been a rare book dealer for more than 40 years, and he is well-aware of the impact that research can have on future generations, having funded history research fellowships at 13 different institutions. When he was diagnosed with prostate cancer in 2013, he maintained this attitude through his gift to Dr. Daniel Petrylak, a groundbreaking physician and researcher at Smilow, and Bill's oncologist.

"In my opinion, an optimistic view is the best view to have when facing cancer," Bill said. "There is reason to hope. The pace and development of new therapies is amazing, and we must keep it moving forward."



[Read More >>](#)

---

**Follow Yale Cancer Center on Twitter**

Screening: Implementation of Evidence-based Approaches.

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

**Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS) (UG3/UH3)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

**Human Tumor Atlas Network: Data Coordinating Center (U24)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)


**Pre-Cancer Atlas (PCA) Research Centers (U2C)**


This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem.


**Letter of Intent and Application Deadlines:**


Follow us on 


**LATEST TWEETS:**


 YCC's Dr. Max Stahl was featured on Oncology TV talking about, "The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with R/R AML Treated with Hypomethylating Agents." [http://minutece.com/Video/program/133 ...](http://minutece.com/Video/program/133...)


 It's a wrap @ASH\_hematology#ASH2017. Thanks to all the YCC researchers and clinicians who made the trip to Atlanta and presented their important discoveries this year.


 Amazing breaking news!!! Yale Institute for Global Health launch @YaleGH

 Medical marijuana for pediatric patients? YCC doctor Prassana Ananth led a new study out today showing pediatric cancer providers give it a cautious thumbs up.

 Watch YCC doctor Amer Zeidan live on CBS Atlanta (go to <http://cbs46.com>) right now talking about the latest in blood cancer research @ASH\_hematology.

 Management for Immunotherapy-Related Adverse Events <http://ow.ly/xbsv30h9XBc> via @YaleCancer#cancertreatment

 It was an overflow crowd to hear YCC doctor Amer Zeidan present his research concerning patients with advanced hematologic malignancies @ASH\_hematology. #ASH17

 Congrats to Dr. Maximilian Stahl @ASH\_hematology! Under the mentorship of Dr. Amer Zeidan, he was given two prestigious awards at this year's conference. #ASH2017

 Modifying RNA to fight #cancer -



December 18, 2017; January 18, 2018

[Learn More >>](#)

### **Human Tumor Atlas Research Centers (U2C)**

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem.

#### **Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

### **Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)**

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.

**Application Due Date:** January 8, 2018

[Learn More >>](#)

### **The Howard Hughes Medical Institute - The Hanna H. Gray Fellows Program Competition**

The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals who are from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those from disadvantaged backgrounds, early in their careers.

**Application Deadline:** January 10, 2018

[Learn More >>](#)


### **2018 Translational Research Grant**


Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a \$500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.


**Application Deadline:** January 15, 2018


[Learn More >>](#)


new research by .@YaleCancer's Dr. Sam Katz via .@EdStannardNHR .@YaleMed


 Dr. Maximilian Stahl @ASH\_hematology has given two oral and two poster presentations so far, with more to come! He's a shining star as a member of our Yale Cancer Center junior faculty! #ASH2017


 Annual tradition: Nimer lab alumni getting together at #ASH breakfast. Congratulations to all 4 new grants, papers and faculty positions!

 **What's happening**  
@ASH\_hematology? YCC Dr. Scott Huntington is presenting, "Financial Incentives and Rituximab Maintenance: Association of Treatment Location with Prolonged Maintenance in Non-Hodgkin Lymphoma Patients Treated in the United States". #ASH17

 Save the date-Friday 2/2/18 "Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer" Yale's West Campus 8:00AM  
@jamesfarrellGI@YNHH  
@YaleCancer#PancreaticCancer

 Join Yale's .@politikaterina as she discusses new cancer therapies at @TildeCafe this Saturday, December 9! The Tilde Cafe is the oldest continuously running science cafe in Connecticut.

 Read Dr. Kerin Adelson's new research in the Journal of Oncology Practice concerning IMPAC, a novel prognostic tool that can generate life expectancy probabilities in real time and support oncologists in counseling patients about end-of-life care.

 Looking for ways to give back this holiday season? Be a health angel and



### Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1)

This FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory.

#### Letter of Intent and Application Deadlines:

December 17, 2017; January 17, 2018

[Learn More >>](#)

### Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS): Coordinating Center (U24)

The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

#### Letter of Intent and Application Deadlines:

December 18, 2017; January 18, 2018

[Learn More >>](#)

### Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS) (UG3/UH3)

The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

#### Letter of Intent and Application Deadlines:

December 18, 2017; January 18, 2018


[Learn More >>](#)


### Human Tumor Atlas Network: Data Coordinating Center (U24)

The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

check out these ideas from here at Smilow Cancer Hospital and Smilow Care Centers:

<https://www.valemedicine.org/stories/holiday-giving-healthy-causes/>

 Take your health into your own hands and join @SU2C and Smilow Cancer Hospital in celebrating #CancerScreenWeek! Talk to your doctor, visit our website, or call us to learn more about what screenings you can do today to protect your health

 Yale Cancer Center clinicians and researchers, including Lajos Pusztai, MD, DPhil, Erin Hofstatter, MD, and David Rimm, MD, PhD, are among thousands presenting critical breast cancer research at this year's @SABCSSanAntonio. #SABCS17

 @CTDPH  
Commissioner Raul Pino addresses guests at the CT Cancer Partnership annual meeting

---

## Closer to Free

# closer to free

The fund to advance cancer research and enhance patient care

---

## Calendar of Events

**December 15; 1:00PM**

### Developmental Therapeutics Research Program

SHM I-116  
*Mechanisms of Invasiveness in Cholangiocarcinoma: A Potential Therapeutic Target"*  
Mario Strazzabosco, MD, PhD

[Read More >>](#)

**December 17; 7:30PM**

### Yale Cancer Answers

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

**Pre-Cancer Atlas (PCA) Research Centers (U2C)**

The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

**Human Tumor Atlas Research Centers (U2C)**

The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem.

**Letter of Intent and Application Deadlines:**

December 18, 2017; January 18, 2018

[Learn More >>](#)

**Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)**

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.

**Application Due Date:** January 8, 2018

[Learn More >>](#)

**The Howard Hughes Medical Institute - The Hanna H. Gray Fellows Program Competition**

The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals who are from gender, racial, ethnic, and other groups underrepresented in the life

WNPR

*Palliative Care for Patients Does Not Mean End-of-Life Care*

Laura Morrison, MD

[Read More >>](#)

**December 18; 12:00PM**

**Hematology Special Seminar**

BCMM 206/208

*Next Generation Sequencing Detects New Variation Associated with Blood Traits*

Jill Johnsen, MD

[Read More >>](#)

**December 19; 12:00PM**

**Yale Cancer Center Schwartz Rounds**

Park Street Auditorium

*Unexpected Gifts: Caring for Someone with a Serious Life-Threatening Illness*

Stacey Stein, MD

[Read More >>](#)

**December 19; 4:00PM**

**Human and Translational Immunology Seminar**

TAC N107

*Adapting to Tumor Microenvironments*

Susan Kaech, MD

[Read More >>](#)

**December 20; 12:00PM**

**Seminar**

FMB 115

*Anal Cancer: Current Developments of an Orphan Malignancy*

Cathy Eng, MD, FACP

[Read More >>](#)

**December 21; 12:30PM**

**Pathology Grand Rounds**

LMP 1094

*Fishing for the Cure: Molecular Insights into Amyloid Cardiomyopathy*

Ronghli Liao, PhD

[Read More >>](#)

**December 21; 7:30PM**

**Smilow Cancer Genetics and Prevention Program Seminar**

330 Orchard Street, Suites 107-109

sciences, including those from disadvantaged backgrounds, early in their careers.

**Application Deadline:** January 10, 2018

[Learn More >>](#)

#### **2018 Translational Research Grant**

Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a \$500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.

**Application Deadline:** January 15, 2018

[Learn More >>](#)

#### **Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)**

The main goals for this initiative include: a) Development of racially/ethnically diverse PDX models; b) Development of methods for preclinical testing of single agents and drug combinations; and c) Conducting response studies of PDX models, primarily from racially/ethnically diverse populations, to develop novel therapeutic strategies.

**Application Due Date:** January 18, 2018

[Learn More >>](#)

#### **Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)**

The goals for this FOA include the development of translational research programs focused upon investigating cancer health disparities.

**Application Due Date:** January 18, 2018

[Learn More >>](#)

#### **Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)**

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers.

**Application Due Date:** January 29, 2018

[Learn More >>](#)

[Read More >>](#)

**December 24; 5:00PM**

#### **Yale Cancer Answers**

WNPR

*Nutritional Tips to Help During the Holiday Season*

Heidi Larson, RD; Amy Bragagnini, RD

[Read More >>](#)

**December 28; 2:30PM**

#### **Smilow Cancer Genetics and Prevention Program Seminar**

330 Orchard Street, Suites 107-109

[Read More >>](#)

**December 31; 7:30PM**

#### **Yale Cancer Answers**

WNPR

*Donating Blood to Support Cancer Patients - Giving During the Holiday Season*

Edward L. Snyder, MD;

Bernadette West, MD

[Read More >>](#)

**January 2; 12:00PM**

#### **Yale Cancer Center Grand Rounds**

Park Street Auditorium

Craig Crews

Topic TBD

[Read More >>](#)

**January 4; 12:00PM**

#### **Hematology Special Seminar**

FMP 115

*Thrombopoietin Receptor Agonists: Past, Present, and Future*

Hanny Al-Samkari, MD

[Read More >>](#)

**January 4; 12:30PM**

#### **Pathology Grand Rounds**

LMP 1094

*Podocyte Injury, Adaptive Glomerulosclerosis, and Chronic Kidney Disease: Role of Non-Muscle Myosin IIA*

Joel Henderson, MD, PhD

[Read More >>](#)

**January 4; 2:30PM**

### **A Breath of Hope Lung Foundation**

A Breath of Hope Lung Foundation is proud to announce the \$150,000 Tona Vives Research Award. A Breath of Hope Lung Foundation (ABOHLF) is a young, growing nonprofit that intends to support creative researchers as they pursue bold research that could result in prolonged or saved lives and large contributions to science. Focused on the topic of understanding lung cancer in women, A Breath of Hope Lung Foundation is now accepting applications.

To confirm your eligibility to apply for this funding and receive the online application, please complete the [online form](#).

**Application Due Date:** February 1, 2018

---

## **Recent Publications**

### **Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease.**

Curtis S, Brandow AM.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):542-545.

[Read More >>](#)

### **Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock.**

Gross CP, Gluck AR.

J Clin Oncol. 2017 Dec 13;JCO2017760488.

[Read More >>](#)

### **Activity of the PI3K- $\delta$ , $\gamma$ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.**

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM.

Blood. 2017 Dec 12. pii: blood-2017-08-802470.

[Read More >>](#)

### **Smilow Cancer Genetics and Prevention Program Seminar**

330 Orchard Street, Suites 107-109

[Read More >>](#)

---

## **Submissions**

Please submit your recent publication and grant announcements to:

### **Renee Gaudette**

Director, Public Affairs and Marketing

[renee.gaudette@yale.edu](mailto:renee.gaudette@yale.edu)





**Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.**

Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS.

Clin Colorectal Cancer. 2017 Oct 24.

[Read More >>](#)

**Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies.**

Khalaf N, Yuan C, Hamada T, Cao Y, Babic A, Morales-Oyarvide V, Kraft P, Ng K, Giovannucci E, Ogino S, Stampfer M, Cochrane BB, Manson JE, Clish CB, Chan AT, Fuchs C, Wolpin BM.

Gastroenterology. 2017 Dec 8.

[Read More >>](#)

**Progress in the Treatment of Hodgkin's Lymphoma.**

Longo DL, DeVita VT Jr.

N Engl J Med. 2017 Dec 10.

[Read More >>](#)

**Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States.**

Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB.

J Natl Compr Canc Netw. 2017 Dec;15(12):1494-1502.

[Read More >>](#)

**Missed Opportunities for HPV Immunization Among Young Adult Women.**

Oliveira CR, Rock RM, Shapiro ED, Xu X, Lundsberg L, Zhang LB, Garipey A, Illuzzi JL, Sheth SS.

Am J Obstet Gynecol. 2017 Dec 6.

[Read More >>](#)

**CRISPR-Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing.**

Moreno-Mateos MA, Fernandez JP, Rouet R, Vejnar CE, Lane MA, Mis E, Khokha MK, Doudna JA, Giraldez AJ.

Nat Commun. 2017 Dec 8;8(1):2024.

[Read More >>](#)

**Yale school of public health symposium on lifetime exposures and human health: the exposome; summary and future reflections.**

Johnson CH, Athersuch TJ, Collman GW, Dhungana S, Grant DF, Jones DP, Patel CJ, Vasiliou V.

Hum Genomics. 2017 Dec 8;11(1):32.

[Read More >>](#)

**Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.**

Doroshov DB, LoRusso PM.

Future Oncol. 2017 Dec 7.

[Read More >>](#)

**Connections Between Hospital Financial Distress, Physician Incentive, and Patient Access to Breast Reconstruction.**

Avraham T, Gross CP, Killelea BK.

JAMA Surg. 2017 Dec 6.

[Read More >>](#)